LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.

Photo from archive.org

Sex Male 10 (83.3%) Female 2 (16.7%) Age (years), median (range) 61 (52—74) Comorbidities, median (range) 1.5 (1—4) Smoking 8 (66.7%) Diabetes mellitus 6 (50%) High blood pressure 5 (41.7%)… Click to show full abstract

Sex Male 10 (83.3%) Female 2 (16.7%) Age (years), median (range) 61 (52—74) Comorbidities, median (range) 1.5 (1—4) Smoking 8 (66.7%) Diabetes mellitus 6 (50%) High blood pressure 5 (41.7%) Hyperlipidemia 2 (16.7%) Pancreatic tumor location Head 8 (66.7%) Body 3 (25%) Tail 1 (8.3%) Metastatic sites, median (range) 1.5 (1—3) Liver — (exclusive) 11 (91.7%) — 5 (41.7%) Peritoneum 2 (16.7%) Adrenal gland 1 (8.3%) First-line chemotherapy Folfirinox 12 (100%) Number of cycles, median (range) 9 (2—36)

Keywords: nab paclitaxel; could combination; range; combination nab; median range; paclitaxel plus

Journal Title: Clinics and research in hepatology and gastroenterology
Year Published: 2017

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.